The short answer
A bleeding interaction between ginger root powder and dalteparin has not been established. Human powdered-ginger studies have mixed platelet findings, including null results, and do not provide a universal avoidance or spacing rule.
What this answer covers
Zingiber officinale dried rhizome powder, commonly sold as root powder; not fresh juice, oil or a concentrated extract. Dalteparin means subcutaneous dalteparin sodium.
- Supplement or preparation
- Zingiber Officinale (Ginger) Root Powder
- Medication ingredient
- dalteparin
Some powder studies found no effect
Eight healthy men took a single 2 g dried-ginger dose or placebo, with no difference in bleeding time or measured platelet tests. Another study found no platelet-aggregation change with 4 g/day powdered ginger for three months. Neither establishes safety during dalteparin treatment.
A higher single dose changed a surrogate
The latter study found reduced platelet aggregation after a separate 10 g single dose. That is a laboratory response rather than proof of clinical bleeding or a dalteparin interaction. The contrast does not define a safe dose threshold.
Current monograph and preparation limits
The European ginger monograph lists no known interactions for its covered preparations. This does not mean dalteparin co-use was tested. Evidence from powder should not be silently transferred to extracts or fresh ginger, and the actual botanical preparation remains important.
No established spacing solution
Tell the dalteparin team about the exact supplement before starting or changing it. Report unusual bleeding or bruising promptly; serious bleeding, black stools or vomiting blood needs urgent assessment. Do not change prescribed dalteparin yourself. No reviewed evidence establishes a universal stop rule or a protective interval between ginger powder and dalteparin.
Evidence and practical considerations
Side effects & toxicity
No direct dalteparin clinical bleeding evidence; indirect original human findings include null results and cannot establish this broad increased-risk claim.
- Exact scope
- Zingiber officinale dried rhizome powder, commonly sold as root powder; not fresh juice, oil or a concentrated extract. Dalteparin means subcutaneous dalteparin sodium. with Subcutaneous dalteparin sodium; active ingredient bridge to RxCUI67109 IN. Not UFH or another LMWH.
- Medication form and route
- subcutaneous dalteparin; oral supplement
What remains uncertain
- Source-specific population, preparation and endpoint limits apply; no universal dose or timing rule.
Factors that may matter: Exact preparation; Dose and duration; Kidney function; Other medicines.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients receiving subcutaneous dalteparin sodium.
Bleeding risk can increase with platelet inhibitors and other anticoagulants. Hyperkalemia is listed among postmarketing reports, whose frequency and causal relationship cannot reliably be established.
How this applies: Exact dalteparin sodium injection product and route; no silent transfer of unfractionated-heparin dosing or monitoring rules.
Does not specifically name these supplements. Not unfractionated heparin, another LMWH, an oral anticoagulant or topical therapy.
Source 2: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Eight healthy men.
No difference in bleeding time, platelet count, thromboelastography or aggregation versus placebo.
How this applies: Exact species, preparation, route and measured endpoints govern applicability; other anticoagulants are not silently treated as dalteparin.
Eight volunteers, no dalteparin; short surrogate study cannot establish long-term safety or a safe dose threshold.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Coronary artery disease participants; subgroup counts absent from abstract.
Powdered ginger4g/day for three months did not change platelet aggregation; a separate10g single dose reduced aggregation.
How this applies: Exact species, preparation, route and measured endpoints govern applicability; other anticoagulants are not silently treated as dalteparin.
Clinical bleeding and exact dalteparin co-use not established in abstract; dose-dependent surrogate findings do not set a safe supplement dose.
Source 4: regulatory herbal monograph
ema.europa.eu · Source check Sep 10, 2026
Population: Users of the specified preparation.
No known interactions listed for covered preparations.
How this applies: Exact species, preparation, route and measured endpoints govern applicability; other anticoagulants are not silently treated as dalteparin.
No known interaction is not evidence of tested dalteparin safety; commercial name root powder refers to rhizome material and must be confirmed.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact dalteparin article with independently checked product label and explicit limits on indirect supplement evidence. | |
| Research summary published |
Article revision: 6745fb20d373d025
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.